Trial Profile

A US Multi-center, Prospective, Non-interventional, Long Term, Effectiveness and Safety Study of Patients Treated With SKYTROFA (Lonapegsomatropin)

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 02 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lonapegsomatropin (Primary)
Indications Somatotropin deficiency
Focus Adverse reactions; Therapeutic Use
Acronyms SkybriGHt
Sponsors Ascendis Pharma

Most Recent Events

30 May 2024 According to an Ascendis Pharma media release, baseline demographics and design of the SkybriGHt study, to be presented during ENDO 2024, the annual meeting of the Endocrine Society being held June 1-4, 2024, in Boston.
25 Apr 2023 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com